Skip to main content

Market Overview

7 Stocks Moving In Tuesday's After-Hours Session



  • Caladrius Biosciences Inc (NASDAQ: CLBS) shares are up 34 percent after announcing the company’s CD34+ cell therapy program received FDA regenerative medicine advanced therapy designation for treating refractory angina.
  • Forterra Inc (NASDAQ: FRTA) shares are up 16 percent after reporting a first-quarter earnings beat. Earnings came in at $(0.31), beating estimates by 13 cents. Sales came in at $290 million, missing estimates by $22 million. The company sees second-quarter adjusted EBITDA of $50-$58 million.


  • Anika Therapeutics Inc (NASDAQ: ANIK) shares are down 25 percent after reporting top-line results from CINGAL 16-02 clinical trial in knee osteoarthritis study did not achieve statistical significance at primary endpoint.
  • La-Z-Boy Incorporated (NYSE: LZB) shares are down 4 percent after reporting a fourth-quarter sales miss. Adjusted earnings came in at 66 cents per share, beating estimates by 2 cents. Sales came in at $420 million, missing estimates by $7 million.
  • Oracle Corp (NYSE: ORCL) shares are down 3.5 percent following a fourth-quarter earnings beat, however, guidance came in lower than expected.
  • Apollo Endosurgery Inc (NASDAQ: APEN) shares are down 3 percent after announcing the commencement of a common stock offering. The size was not disclosed.
  • Starbucks Corp (NASDAQ: SBUX) shares are down 1.8 percent after announcing weak third-quarter guidance and the closing of 150 stores.

Related Articles (CLBS + FRTA)

View Comments and Join the Discussion!

Posted-In: News After-Hours Center Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at